September 2016 Issue Table Of Contents

From The Editor

• Where Will The Next Biopharma Breakthrough Come From?

Feature Articles

• Will GSK’s Deal With Novartis Pay Off For Its Vaccine Aspirations?
• Cancer Immunotherapy - Simpler Or More Complex?

The Enterprisers

• How Rebiotix Avoids The Typical Biopharma Startup Missteps

Capitol Perspectives

• Rx Industry Vulnerable On Generic Delay In Fall

Companies To Watch

• Quark Pharmaceuticals

CEO Corner

• Drug Company Discovery & Commercialization: An Election Year Analogy

Inside The Industry

• Driving Innovation In Life Sciences With Agile
• The Common Elements Of Top-Performing Pharmas
• Is Your Board Capable Of Overseeing IT?
• The Increasing Importance Of Real-World Evidence In Drug Development

Leadership Lessons

• How To Be A Three-Box Leader

Industry Leader

• Great Expectations For Personalized Medicine Outside Oncology

Ask The Board

• What Clinical Trial Requirements Or Practices Could Be Revised To Provide Quick Cost Reductions And Perhaps Result In Lower Drug Prices?
• List Some Key Characteristics You Look For When Recruiting Engineers And How To Tease These Out.
• What Are Some Fundamental Challenges Facing Biopharma Manufacturers?